14.37

0.35% 0.05

After Hours: 14.38 0.01 +0.07%

Lyell Immunopharma Inc (LYEL)

Overview News Price History Option Chain Financials Discussions Forecast

Lyell Immunopharma Inc stock is traded at $14.37, with a volume of 54,064. It is up +0.35% in the last 24 hours and up +5.66% over the past month. Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Previous Close:

$14.32

Open:

$14.29

24h Volume:

54,064

Relative Volume:

0.30

Market Cap:

$352.14M

Revenue:

$31,000

Net Income/Loss:

$-246.41M

P/E Ratio:

-1.1281

EPS:

-12.7377

Net Cash Flow:

$-134.42M

1W Performance:

-1.10%

1M Performance:

+5.66%

6M Performance:

-39.62%

1Y Performance:

+22.61%

1-Day Range:

$13.92

$14.68

1-Week Range:

$13.92

$15.14

52-Week Range:

$11.47

$45.00

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Name

Lyell Immunopharma Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

650 695-0677

Address

201 HASKINS WAY, SOUTH SAN FRANCISCO

Employee

161

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

LYEL's Discussions on Twitter

Compare LYEL vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LYEL Lyell Immunopharma Inc	14.37	376.15M	31,000	-246.41M	-134.42M	-12.74
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Needham	Buy
Mar-09-26	Initiated	Citizens	Mkt Outperform
Dec-09-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-30-24	Downgrade	BofA Securities	Buy → Underperform
Jun-27-24	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-11-22	Downgrade	Goldman	Buy → Neutral
Oct-17-22	Initiated	H.C. Wainwright	Buy
Jul-12-21	Initiated	BofA Securities	Buy
Jul-12-21	Initiated	Goldman	Buy
Jul-12-21	Initiated	JP Morgan	Overweight
Jul-12-21	Initiated	Morgan Stanley	Overweight

View All

Lyell Immunopharma Inc Stock (LYEL) Latest News

Sep 04, 2026

Lyell Immunopharma stock holds steady as investors await fresh clinical and cash-flow signals - AD HOC NEWS

Sep 04, 2026

Aug 27, 2026

This Insider Has Just Sold Shares In Lyell Immunopharma - simplywall.st

Aug 27, 2026

Aug 25, 2026

Lyell Immunopharma (LYEL) CEO sells shares for taxes, keeps 63,899 - Stock Titan

Aug 25, 2026

Aug 24, 2026

Lyell (LYEL) Outlook: Closes 4.57% Lower at $14.82 in the Latest Session; Next Session: the $14.08 to $15.56 Range Remains in Focus at the ClosePassive Flow - vinanet.vn

Aug 24, 2026

Aug 14, 2026

Lyell Immunopharma (LYEL): Foresite funds and Tananbaum report 2.7% ownership - Stock Titan

Aug 14, 2026

Citizens reiterates Lyell Immunopharma stock rating on pipeline progress By Investing.com - Investing.com Canada

Aug 14, 2026

Aug 13, 2026

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Aug 13, 2026

Aug 12, 2026

Lyell Immunopharma (LYEL) Slides 4.77% to $14.17 as Biotech Risk Appetite FadesTriple Top - dars.gov.et

Aug 12, 2026

Aug 11, 2026

Lyell Immunopharma VP Bulis sells $8,905 of common stock By Investing.com - Investing.com UK

Aug 11, 2026

Lyell Immunopharma VP Veronica Sanchez Bulis Sells 621 Shares for Tax Withholding on August 10, 2026 - Kalkine Media

Aug 11, 2026

Lyell Immunopharma COO Stephen J. Hill Sells Shares to Cover Tax Withholding on RSU Settlement - Kalkine Media

Aug 11, 2026

Lyell Immunopharma (LYEL) CSO auto-sells shares to cover RSU tax withholding - Stock Titan

Aug 11, 2026

Lyell Immunopharma VP Bulis sells $8,905 of common stock - Investing.com

Aug 11, 2026

Lyell Immunopharma CSO Executes Automatic Stock Sale to Meet Tax Withholding Requirements - Kalkine Media

Aug 11, 2026

Lyell Immunopharma (LYEL) VP auto-sells 621 shares to cover RSU taxes - Stock Titan

Aug 11, 2026

Lyell Immunopharma (LYEL) COO auto-sells 89 shares for RSU tax withholding - Stock Titan

Aug 11, 2026

Lyell Immunopharma (LYEL) CEO sells shares to cover RSU tax withholding - Stock Titan

Aug 11, 2026

Renaissance Technologies LLC Buys 76,921 Shares of Lyell Immunopharma, Inc. $LYEL - MarketBeat

Aug 11, 2026

Aug 10, 2026

Lyell Immunopharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Aug 09, 2026

Lyell Immunopharma earnings beat by $0.22, revenue fell short of estimates - Investing.com Canada

Aug 09, 2026

Aug 08, 2026

Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - webull.com

Aug 08, 2026

Lyell Immunopharma (NASDAQ:LYEL) Posts Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat

Aug 08, 2026

Aug 07, 2026

Lyell Immunopharma, Inc. expected to post a loss of $2.08 a shareEarnings Preview - TradingView

Aug 07, 2026

Aug 06, 2026

Lyell Immunopharma: Q2 Earnings Snapshot - AOL.com

Aug 06, 2026

Lyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingView

Aug 06, 2026

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 - manilatimes.net

Aug 06, 2026

BRIEF-Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million - TradingView

Aug 06, 2026

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga

Aug 06, 2026

Lyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus - MarketBeat

Aug 06, 2026

Stifel Initiates Lyell Immunopharma(LYEL.US) With Buy Rating, Announces Target Price $36 - Moomoo

Aug 06, 2026

Aug 05, 2026

LYELL IMMUNOPHARMA, INC. : STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $36 - Bitget

Aug 05, 2026

Stifel initiates Lyell Immunopharma stock with buy rating on CAR T therapy - Investing.com South Africa

Aug 05, 2026

LYEL Q2'26 Earnings: revenue estimate is 4.60K USD - TradingView

Aug 05, 2026

Aug 04, 2026

Lyell Immunopharma (LYEL) Projected to Post Quarterly Earnings on Tuesday - MarketBeat

Aug 04, 2026

Jul 29, 2026

Price to book forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL - TradingView

Jul 29, 2026

Jul 27, 2026

Form 4 Lyell Immunopharma Inc For: 27 July By Investing.com - Investing.com Nigeria

Jul 27, 2026